Key facts
- Notable investors include SF Express, Yizhuang Guotou.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Likang Life Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Likang Life Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Likang Life Sciences
Developer of immune cell therapy intended to serve the tumor treatment industry. The company specializes in the development of immune cell therapy with tumor-specific neoantigen as the target and provides personalized diagnosis and treatment services for cancer patients with precise detection and treatment methods.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Website
- likanglife.com/
- Ownership
- Privately Held (backing)
Likang Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Likang Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Likang Life Sciences in its N-PORT filings yet. We sweep new filings monthly.